2013
DOI: 10.1016/j.ijpharm.2012.12.014
|View full text |Cite
|
Sign up to set email alerts
|

Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
4
3
1

Relationship

2
6

Authors

Journals

citations
Cited by 28 publications
(17 citation statements)
references
References 26 publications
0
17
0
Order By: Relevance
“…Prepared patches were cut into 3.14 cm 2 pieces and weight of each patch was determined by using digital balance. The average weight of each patch and standard deviations were calculated [15,16].…”
Section: Evaluation Of Transdermal Patches 241 Weight Variationmentioning
confidence: 99%
“…Prepared patches were cut into 3.14 cm 2 pieces and weight of each patch was determined by using digital balance. The average weight of each patch and standard deviations were calculated [15,16].…”
Section: Evaluation Of Transdermal Patches 241 Weight Variationmentioning
confidence: 99%
“…Patches are commercially available for a constant delivery of various substances like ethinyl estradiol (Sachdeva et al 2013), fentanyl (Lehmann and Zech 1992), lignocaine (Kwon et al 2012), nicotine (Benowitz et al 1991), nitroglycerol (Minghetti et al 2001), rivastigmine (Gauthier et al 2013), rotigotine (Stiasny-Kolster et al 2013), scopolamine (Gil et al 2012), testosterone (James 1995), and others. Such a new preparation is a patch, which represents a sophisticated drug delivery system with the intent to release the active compound in such a manner that the dosing frequency can be reduced in comparison to conventional dosage forms (FDA 2013).…”
Section: Special Formulation Typesmentioning
confidence: 99%
“…Such a new preparation is a patch, which represents a sophisticated drug delivery system with the intent to release the active compound in such a manner that the dosing frequency can be reduced in comparison to conventional dosage forms (FDA 2013). Due to drug storage within the patch, transdermal patches can be classified into three types: (1) drug directly dispersed in adhesive polymer, (2) drug reservoir between a rate con-trolling membrane and a backing membrane, and (3) drug reservoir within the center of a peripheral adhesive ring around the edges (Sachdeva et al 2013). The main advantages of patches are sustained and constant plasma levels and the bypass of the first-pass effect in the liver (Kapil et al 2012).…”
Section: Special Formulation Typesmentioning
confidence: 99%
“…Slide crystallization studies were performed to identify the appropriate drug concentration in the patch at which the drug does not crystallize during its storage 20 . Different formulations of drug-in-adhesive at various w/w ratios were prepared and smeared on histological slides and were allowed for 24 h at room temperature to evaporate the organic solvents.…”
Section: Slide Crystallization Studiesmentioning
confidence: 99%